sr9009-notes.peptides5388.com › Wiki › Detection, Regulation, And Misconceptions — Background and Details

Detection, Regulation, And Misconceptions — Background and Details

By Editorial Desk · published 2025-01-06 · last reviewed 2025-01-31 · Wiki

Stenabolic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-01-31. Numbers and descriptions here follow the published literature rather than marketing material.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved for human useResearch-use-only status in many markets
WADA statusProhibited in sportGenerally listed as a non-approved substance
Detection techniqueLC-MS/MSCommon for urine and blood analysis
Common aliasStenabolicInformal market nickname, not a pharmacopoeial name
Purity checkHPLC or LC-UVIndependent certificate of analysis is typical

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Related pages on this site

Further detail

detailed family history conducting a detailed physical examination to document morphological features testing for genetic defect in FGDY1 x-rays can identify skeletal abnormalities echo cardiogram can screen for heart abnormalities CT scan of the brain for cystic development X-ray of the teeth Ultrasound of abdomen to identify undescended testis Similar to all genetic diseases Aarskog–Scott syndrome cannot be cured, although numerous treatments exist to increase the quality of life. Surgery may be required to correct some of the anomalies, and orthodontic treatment may be used to correct some of the facial abnormalities. Trials of growth hormone have been effective to treat short stature in this disorder. Some people may have some mental slowness, but children with this condition often have good social skills. Some males may have problems with fertility. The syndrome is named for Dagfinn Aarskog, a Norwegian pediatrician and human geneticist who first described it in 1970, and for Charles I. Scott, Jr., an American medical geneticist who independently described the syndrome in 1971.

Discovered by Tillett and Francis in 1930, it was initially thought that CRP might be a pathogenic secretion since it was elevated in a variety of illnesses, including cancer. The later discovery of hepatic synthesis (made in the liver) demonstrated that it is a native protein. Initially, CRP was measured using the quellung reaction which gave a positive or a negative result. More precise methods nowadays use dynamic light scattering after reaction with CRP-specific antibodies. CRP was so named because it was first identified as a substance in the serum of patients with acute inflammation that reacted with the cell wall polysaccharide (C-polysaccharide) of pneumococcus.

Berg did not complete his final step due to the pleas of several fellow investigators, including Robert Pollack, who feared the biohazards associated with the last step. The SV40 was known to cause cancer tumors to develop in mice. Additionally, the E. coli bacterium (although not the strain used by Berg) inhabited the human intestinal tract. For these reasons, the other investigators feared that the final step would create cloned SV40 DNA that might escape into the environment and infect laboratory workers. These workers could then become cancer victims. Concern about this potential biohazard, along with others, caused a group of leading researchers to send a letter to the president of the National Academy of Sciences (NAS). In this letter, they requested that he appoint an ad hoc committee to study the bio-safety ramifications of this new technology. This committee, called the Committee on Recombinant DNA molecules of the National Academy of Science, U.S.A., held in 1974, concluded that an international conference was necessary to resolve the issue and that until that time, scientists should halt experiments involving recombinant DNA technology.

Large aromatic residues (tyrosine, phenylalanine, tryptophan) and β-branched amino acids (threonine, valine, isoleucine) are favored to be found in β-strands in the middle of β-sheets. Different types of residues (such as proline) are likely to be found in the edge strands in β-sheets, presumably to avoid the "edge-to-edge" association between proteins that might lead to aggregation and amyloid formation. A very simple structural motif involving β-strands is the β-hairpin, in which two antiparallel strands are linked by a short loop of two to five residues, of which one is frequently a glycine or a proline, both of which can assume the dihedral-angle conformations required for a tight turn or a β-bulge loop. Individual strands can also be linked in more elaborate ways with longer loops that may contain α-helices.

Sources: en.wikipedia.org

Supporting material

The most common peptide aptamer selection system is the yeast two-hybrid system. Peptide aptamers can also be selected from combinatorial peptide libraries constructed by phage display and other surface display technologies such as mRNA display, ribosome display, bacterial display and yeast display. These experimental procedures are also known as biopanning. All the peptides panned from combinatorial peptide libraries have been stored in the MimoDB database.

In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry). In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called "area under the curve" or AUC) gives insight into the extent of exposure to a drug and its clearance rate from the body.

Cell biology is the branch of biology that studies the structure, function, and behaviour of cells. Bioenergetics is a field in biochemistry and cell biology that concerns energy flow through living systems. This is an active area of biological research that includes the study of the transformation of energy in living organisms and the study of thousands of different cellular processes such as cellular respiration and other metabolic and enzymatic processes that enable the use of energy. Genetics is the scientific study of inheritance. Classical genetics, specifically, is the study of how genes and traits are passed on from parents to offspring; its principles are called Mendelian inheritance. A Punnett square can be used to predict the results of a test cross. The chromosome theory of inheritance, which states that genes are found on chromosomes, was supported by Thomas Morgans's experiments with fruit flies, which established the sex linkage between eye color and sex in these insects.

Acids are fundamental reagents in treating almost all processes in modern industry. Sulfuric acid, a diprotic acid, is the most widely used acid in industry, and is also the most-produced industrial chemical in the world. It is mainly used in producing fertilizer, detergent, batteries and dyes, as well as used in processing many products such like removing impurities. According to the statistics data in 2011, the annual production of sulfuric acid was around 200 million tonnes in the world. For example, phosphate minerals react with sulfuric acid to produce phosphoric acid for the production of phosphate fertilizers, and zinc is produced by dissolving zinc oxide into sulfuric acid, purifying the solution and electrowinning. In the chemical industry, acids react in neutralization reactions to produce salts. For example, nitric acid reacts with ammonia to produce ammonium nitrate, a fertilizer. Additionally, carboxylic acids can be esterified with alcohols, to produce esters. Acids are often used to remove rust and other corrosion from metals in a process known as pickling. They may be used as an electrolyte in a wet cell battery, such as sulfuric acid in a car battery.

Akt regulates TFEB, a master controller of lysosomal biogenesis, by direct phosphorylation of TFEB at serine 467. Phosphorylated TFEB is excluded from the nucleus and less active. Pharmacological inhibition of Akt promotes nuclear translocation of TFEB, lysosomal biogenesis and autophagy. Akt promotes G1-S phase cell cycle progression by phosphorylating and inactivating glycogen synthase kinase 3 (GSK-3) at Ser9. This prevents the phosphorylation and degradation of cyclin D1.

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

How is SR9009 detected in doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.

Why is SR9009 called Stenabolic?

Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network